An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The investigational study drug, JNJ-64281802, is being developed for the prevention and
treatment of dengue infection. This study is hypothesizing that the highest dose of the
investigational study drug is superior to receiving a placebo with respect to its antiviral
activity in healthy adult participants inoculated with Dengue Serotype 3.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)